Journal article · 2025
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study
Annals of Internal Medicine, 179(2), 168–176 · Published 22 December 2025 · DOI 10.7326/annals-25-01939
In brief
“Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study” is a 2025 journal article by Amy E. Colson and 22 co-authors, published in Annals of Internal Medicine. OpenAlex counts 26 citations as of 17 November 2026, which puts it in the top 1% of works published in 2025 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 26
- Most cited in
- 2026 (26)
- Field-weighted impact
- 14.12
- References
- 20
- Authors
- 23
Abstract
BACKGROUND: Once-weekly oral islatravir plus lenacapavir (ISL+LEN) has the potential to address adherence challenges with daily HIV-1 treatment. OBJECTIVE: To evaluate efficacy and safety of once-weekly ISL+LEN. DESIGN: Phase 2, randomized, open-label, active-controlled study. (ClinialTrials.gov: NCT05052996). SETTING: 44 U.S. sites. PARTICIPANTS: Adults with HIV-1 RNA viral load of less than 50 copies/mL receiving daily bictegravir… Read the full abstract at the publisher.
Excerpt. This paper is not open access.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Colson, A. E., Crofoot, G. E., Ruane, P. J., Ramgopal, M. N., Dretler, A. W., Nahass, R., Sinclair, G. I., Berhe, M., Roberts, A. D., Applin, S., Brinson, C. C., Jayaweera, D., Workowski, K., Shihadeh, F. D., Liu, S., Klopfer, S. O., Llamoso, C., Madera, S., Dvory‐Sobol, H., . . . Eron, J. J. (2025). Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study. Annals of Internal Medicine, 179(2), 168–176. https://doi.org/10.7326/annals-25-01939
MLA 9
Colson, Amy E., et al. “Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study.” Annals of Internal Medicine, vol. 179, no. 2, 2025, pp. 168–176. https://doi.org/10.7326/annals-25-01939.
Chicago
Colson, Amy E., Gordon E. Crofoot, Peter Jerome Ruane, Moti N. Ramgopal, Alexandra W. Dretler, Ronald Nahass, Gary Ian Sinclair, et al. 2025. “Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study.” Annals of Internal Medicine 179 (2): 168–176. https://doi.org/10.7326/annals-25-01939.
Harvard
Colson, A. E. et al. (2025) ‘Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study’, Annals of Internal Medicine, 179(2), pp. 168–176. doi:10.7326/annals-25-01939.
IEEE
A. E. Colson et al., “Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study,” Annals of Internal Medicine, vol. 179, no. 2, pp. 168–176, 2025, doi: 10.7326/annals-25-01939.
BibTeX
@article{colson2025once,
title = {{Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study}},
author = {Colson, Amy E. and Crofoot, Gordon E. and Ruane, Peter Jerome and Ramgopal, Moti N. and Dretler, Alexandra W. and Nahass, Ronald and Sinclair, Gary Ian and Berhe, Mezgebe and Roberts, Afsoon D. and Applin, Shauna and Brinson, Cynthia C and Jayaweera, DT and Workowski, Kimberly and Shihadeh, F. D. and Liu, Shanyu and Klopfer, Stephanie Olsen and Llamoso, Cyril and Madera, Sharline and Dvory‐Sobol, Hadas and Rhee, Martin S. and Rhee, Elizabeth G. and Baeten, Jared M. and Eron, Joseph J.},
journal = {Annals of Internal Medicine},
year = {2025},
volume = {179},
number = {2},
pages = {168--176},
doi = {10.7326/annals-25-01939},
url = {https://doi.org/10.7326/annals-25-01939}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- HIV-1
- islatravir
- lenacapavir
- bictegravir
- emtricitabine
- tenofovir alafenamide
- weekly dosing
- antiretroviral therapy
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Colson, A. E., Crofoot, G. E., Ruane, P. J., Ramgopal, M. N., Dretler, A. W., Nahass, R., Sinclair, G. I., Berhe, M., Roberts, A. D., Applin, S., Brinson, C. C., Jayaweera, D., Workowski, K., Shihadeh, F. D., Liu, S., Klopfer, S. O., Llamoso, C., Madera, S., Dvory‐Sobol, H., . . . Eron, J. J. (2025). Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1: A Phase 2 Randomized Study. Annals of Internal Medicine, 179(2), 168–176. https://doi.org/10.7326/annals-25-01939
How many times has this paper been cited?
26 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Amy E. Colson, Gordon E. Crofoot, Peter Jerome Ruane, Moti N. Ramgopal, Alexandra W. Dretler, Ronald Nahass, Gary Ian Sinclair, Mezgebe Berhe, Afsoon D. Roberts, Shauna Applin, Cynthia C Brinson, DT Jayaweera and 11 more.
What is the DOI of this paper?
10.7326/annals-25-01939, permanently at https://doi.org/10.7326/annals-25-01939. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.